Cargando…
Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data
Uterine fibroids (UFs) are the most common gynaecological benign disease. Even though often asymptomatic, UFs can worsen women’s health and their quality of life, causing heavy bleeding and anaemia, pelvic discomfort and reduced fertility. Surgical treatment of UFs could be limited by its invasivene...
Autores principales: | Neri, Manuela, Melis, Gian Benedetto, Giancane, Elena, Vallerino, Valerio, Pilloni, Monica, Piras, Bruno, Loddo, Alessandro, Paoletti, Anna Maria, Mais, Valerio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815212/ https://www.ncbi.nlm.nih.gov/pubmed/31695514 http://dx.doi.org/10.2147/IJWH.S185023 |
Ejemplares similares
-
Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2021) -
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
por: Beck, Denise, et al.
Publicado: (2021) -
Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
por: Beck, Denise, et al.
Publicado: (2022) -
Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
por: Al-Hendy, Ayman, et al.
Publicado: (2021) -
Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis
por: Muhammad, Juliawati, et al.
Publicado: (2022)